Drugnews

Why does the U.S.-only Wegovy pill comparison differ from the global ratio?

In its November 10, 2026 analysis of Q3 2026, Drugnews reports Novo Nordisk’s U.S. Wegovy pill revenue at DKK 4.18 billion, approximately US$630 million. Counting all of Eli Lilly’s US$184 million Foundayo revenue as U.S. sales yields the article’s rounded 3.4x comparison. The U.S. allocation for Foundayo is an explicit analytical assumption.

Updated

Geographic scope changes the comparison
MeasureReported resultBasis
Wegovy pill / United StatesDKK 4.18 billionApproximately US$630 million
Foundayo / assumed United StatesUS$184 millionAll reported revenue allocated to the U.S. for this comparison
U.S.-only revenue ratio3.4xRounded comparison under that assumption

The comparison is an article calculation, not an independently reported Foundayo U.S. revenue line or a prescription count.

Read the full analysis

Novo Pill Leads Lilly 4x, Lilly Takes 1/3 of Starts — 2026-11-10